Related Experiment Video
Updated: May 6, 2026

Hepatocyte-specific Ablation in Zebrafish to Study Biliary-driven Liver Regeneration
Published on: May 20, 2015
A Rare Case of Tirzepatide-Induced Hepatotoxicity
Aalam Sohal1, Luis Casanova1, Kris V Kowdley1,2
1Department of Hepatology, Liver Institute Northwest, Seattle, WA.
Abstract:
Tirzepatide is the first dual incretin glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor activator approved for the management of type II diabetes mellitus. This drug was also recently approved by the Food and Drug Administration as a management option for patients with obesity. Tirzepatide has been also reported to be beneficial in reducing liver fat content. Although its efficacy is well described in the literature, no cases of tirzepatide-induced hepatotoxicity have been reported. We report a case of a 37-year-old woman with metabolic syndrome who was noted to have elevated liver enzymes secondary to tirzepatide use.
Related Concept Videos
Teratogenicity
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Drug Toxicity: Risk factors
Drug Toxicity: Allergic Reactions
Drug toxicity: Idiosyncratic Reactions
Hepatic Encephalopathy

